Mindstrong Health operates a digital care platform that uses smartphone-derived digital biomarkers and teletherapy to monitor and treat people with severe mental illnesses such as schizophrenia, bipolar disorder, obsessive-compulsive disorder and major depressive disorder. The company passively measures phone usage and keyboard-timing metrics to assess mental acuity and emotional valence; those measures are currently being validated in clinical trials. It provides access to therapists via phone, video and asynchronous text and positions its offering as a virtual hospital with complex care pathways for this population. Founder Paul Dagum has worked on these monitoring approaches since 2013 and remains the company’s chief scientific officer. Daniel Graf, an ex‑Uber executive, joined as CEO in November as Mindstrong moves from pure R&D toward commercial availability. The company frames the market need as large and costly to the U.S. healthcare system (roughly $20 billion per month) and says its platform could have broader applications across healthcare. Mindstrong Health develops measurement-science solutions and integrated health services designed to detect mental illness early and deliver preemptive care to improve outcomes. The company markets a diagnostic approach and care-delivery model aimed at modernizing mental health treatment. Mindstrong is led by Founder and CEO Paul Dagum and is based in Palo Alto, California. It is backed by a group of investors that includes ARCH Venture Partners, Foresite Capital, Bezos Expeditions, Decheng Capital, Berggruen Holdings, and One Mind Brain Health Impact Fund. Recently the company expanded its Series B financing with an additional $31 million investment. Board changes accompanying the financing include General Catalyst’s Hemant Taneja joining the board and Stephen K. Klasko joining as an independent director. Mindstrong Health develops measurement science that passively and continuously measures brain function through individuals' interactions with smartphones to detect cognitive and mood deterioration early. Its offerings include a patient-facing app, a provider-facing product, and clinical services delivered via a telehealth-enabled engagement and measurement platform. The company says its digital measures predict performance on gold-standard neurocognitive tests and is advancing clinical and translational research across brain health conditions globally. Mindstrong has partnered with pharmaceutical and clinical organizations, including Takeda Pharmaceutical Company Limited and Blackthorn Therapeutics, to apply its technology to identify digital biomarkers in conditions such as schizophrenia and treatment-resistant depression. The company announced a $15 million Series B and will use proceeds to scale the business and advance commercial deployments with partners across healthcare verticals. To date Mindstrong has raised $29 million following a $14 million Series A in June 2017. Mindstrong Health has developed patented science that transforms patterns of interaction on a smartphone into continuous, objective digital biomarkers of mood and cognition. The platform measures processing speed, attention, memory and executive function based on four years of clinical research. Mindstrong's products are in clinical trials with payers, providers, academics and the pharmaceutical industry. The company says its approach delivers real-time, high-resolution measures of brain function that could modernize assessment and intervention in behavioral health. Mindstrong was established in 2014 and is based in Palo Alto, California. In June 2017 it announced a $14 million Series A to support its technology and clinical operations expansion.

Total raised

$160M

Funding rounds

4

Latest round

Series C

Latest activity

May 2020